Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company enlisting the full breadth of the immune system to protect people from serious infectious diseases, today announced that management will be presenting and engaging in 1-1 meetings at the following upcoming investor conferences:

• BioFuture
  • October 6^th, 2023 at 10:00 a.m. ET
  • New York City, New York
  • 1-1 partnering access: https://biofuture.com/one-to-one-meetings/

• BIO Investor Forum
  • October 18^th, 2023 at 1:30 p.m. PT
  • San Francisco, California
  • 1-1 partnering access: https://bif.bio.org/bio-one-one-partnering

About Blue Lake Biotechnology

Blue Lake Biotechnology, Inc. and its affiliate, CyanVac LLC, are developing intranasal vaccines that enlist the full breadth of the immune system to keep people healthy, prevent serious infectious diseases, and save the lives of vulnerable populations. Our platform uses a proprietary parainfluenza virus 5 vector into which a foreign gene from a targeted pathogen is inserted. We have generated a robust clinical-stage pipeline of best-in-class vaccines designed to overcome the limitations of existing vaccine technologies. Our lead product candidates have demonstrated potential for high efficacy and lasting durability with few vaccine-related side effects.

Learn more at https://www.bluelakebiotechnology.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230927801248/en/